Ex vivo rapamycin generates murine Th2 cells that potently abrogate GVHD. We thus hypothesized that rapamycin would generate Th2/Tc2 cells (Th2/Tc2.R cells) that prevent fully MHC-disparate hematopoietic stem cell (HSC) rejection. To test this hypothesis, we utilized a model of rejection involving lethal host irradiation and quantitative host T cell addback [see cohorts, Table] . Th2/Tc2.R cell recipients had consistent alloengraftment (Ͼ99% donor, nϭ9/10; rejection, nϭ1/10); in contrast, control Th2/Tc2 recipients had graft rejection (nϭ9/10) or mixed chimerism (nϭ1/10). Post-BMT host-vs-graft responses (HVGR) were quantified by the following method: (a) spleen cell harvest and enumeration; (b) 24 h host (syngeneic) or donor (allogeneic) dendritic cell stimulation; (c) cell-surface flow cytometry with anti-CD4, anti-CD8 and anti-host antibodies; (d) Miltenyi IFN-gamma cytokine capture flow cytometry; and (d) calculation of absolute number of host anti-donor alloreactive CD4ϩ and CD8ϩ T cells per spleen. Graft rejection controls had increased post-BMT allospecific CD4ϩ and CD8ϩ T cells secreting IFN-g (cohort 3Ͼcohort 2; pϽ .001). Prevention of rejection by donor Th2/Tc2.R cells abrogated this HVGR (cohort 5Ͻcohort 3; pϽ .001); in contrast, donor Th2/Tc2 cells only partially reduced HVGR (cohort 4Ͻcohort 3; pϽ .05). Cohorts 6, 7, 8, and 9 demonstrated that rapamycingenerated donor T cells prevention of HVGR was attributable to both CD4ϩ and CD8ϩ subsets and occurred independent of perforin or fasL molecules associated with clonal deletion mechansims. To evaluate whether alloreactive host T cells were clonally deleted, the fate of 2C TCR transgenic T cells utilized as host T cell addback was evaluated [BALB/c(H-2d) into B6(H-2b) model]. Administration of a low-dose of donor Th2/Tc2.R cells relative to host 2C TCR transgenic cells (200:1 ratio) resulted in actual massive expansion of alloreactive 2C cells (cohort 13Ͼ cohort 11, pϽ.0001), increased allospecific IFN-g release from 2C cells, and a resultant decrease in donor chimerism; in contrast, administration of high-dose Th2/Tc2.R cells (1000:1 ratio) resulted in similar expansion of alloreactive 2C cells, but nominal acquisition allospecific IFN-g secretion (94.480 Ϯ 13.030; cohort 14 vs cohort 13, pϭ.0005) and in-creased donor chimerism (pϽ.0001). Taken together, rapamycin-generated Th2 or Tc2 cells prevent rejection by a mechanism that reduces host allospecificity without allospecific clonal deletion. Background Recipients of allogeneic HSCT frequently require support with parenteral nutrition and immunosuppressive drugs, in expectation of an increased risk of infections associated with hyperglycemia, particularly in the neutropenic period. Previous reports showed that hyperglycemia was associated with morbidity and mortality in ICU (ref van den Verge et al. N Engl J Med. 2001 Nov 8; 345(19) : 1359-67). There was no previous study which assessed the clinical impact of hyperglycemia in patients undergoing myeloablative HSCT. Patients and Methods A cohort of 112 consecutive adult patients with hematological malignancies treated between January 2002 and June 2006 was reviewed retrospectively, and 21 patients were excluded due to graft failure, preexisting infectious diseases or preexisting neutropenia. The remaining 91 patients (Age median 35.5, 18-57) were categorized according to mean fasting blood glucose (BG) level in the neutropenic period: 1) "normoglycemia" (BGՅ110 mg/dl, nϭ28), 2) "mild hyperglycemia" (110ϽBGՅ150 mg/dl, nϭ49) and 3) "moderate and severe hyperglycemia" (150 mg/dlϽBG, nϭ14). Conditioning regimens included BU/CY (nϭ45), CY/TBI (nϭ43) and CA/CY/TBI (nϭ3). GVHD prophylaxis included cyclosporine-(nϭ62) and tacrolimus-based regimens (nϭ29). Stem cell sources included bone marrow (nϭ46), peripheral blood (nϭ41) and cord blood cells (nϭ4). The primary endpoint of this study was the occurrence of febrile neutropenia (FN) and infection during neutropenia. The secondary endpoints were parameters for organ dysfunction, aGVHD, overall survival (OS) and treatment-related mortality (TRM). Re-
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sults There was no significant difference between the 3 groups in the occurrence of FN or documented infection. However, hyperglycemia was significantly associated with organ dysfunction and aGVHD. OS was better and TRM was less in group1 compared with group2 and group3. Conclusion Degrees of hyperglycemia during neutropenia was associated with an increased risk of organ dysfunction and aGVHD, which further led to higher TRM and lower OS. These results support the possibility that intensive glucose control reduces morbidity and mortality after HSCT. INTRODUCTION: Thrombotic microangiopathy is a rare complication after HSCT. Given the different pathophisiology of the disease and high mortality observed, our purpose is evaluating clinical carcteristcs of these patients and risk factors for survival. PATIENTS AND METHODS: From 1991to 2004, 1066 HSCT were performed at HC-UFPR (Curitiba, Brazil). We identified in our database 17 patients with the diagnosis of thrombotic microangiopathy (prevalence of 1.6%). Mϭ4/Fϭ13, Median age(y)ϭ11; Diagnosis included: SAA: 2; Fanconi anemia: 4; Acute leukemias: 7, Others 2.
Conditioning regimen consisted of BUCY in 9/17 (52%); CI ϩ TBI in 3/17 (18%) of the patients, NMA regimens in 18% and others in 12% of the patients. Immunephrophylaxis consisted of CSA and MTX in 52% of the patients.Twelve patients received related and five received unrelated donor transplant.
Marrow was the stem cell source in all but one patient who received cord blood.
Twelve patients were HLA identical, three patients had a class one mismatch, one patients had a class II mismatch and one patient had more than one mismatch.
Median number of cells infused were 2,57 ϫ 108/KG. RESULTS A-GVHD grade II-IV was present in 12 (70%) patients and extensive C-GVHD was present in only 18% of the patients. Median survival was 99 days and estimated overall survival in 25 years is only 15%, despite therapy. Infection was present in all but one patient (94%). Ten patients had serious bacterial infections (58%), eight of them by gram-positive bacteria. Fungal infection was identified in five patients (2 Candida sp and 3 Aspergillus sp). Viral infection was identified in 12 patients (eight of them with CMV positive antigenemia). Causes of death included: A-GVHD in four pt, C-GVHD in 2 patients, infection in 6 patients, bleeding in two patients and persistent disease in one patient. The only significant factor for survival was severe mucositis (more than grade II).
CONCLUSION: 1. OS was extremely low (15%) despite ther-apy; 2. Infection ( specially gram-positive bacterial infections and CMV positive antigenemia) was present at the majority of the patients and was the main cause of death; 3. A-GVHD was present in 52% of the patients; 4. Severe mucositis was associated to a lower survival rate (pϭ0,02). Funke, V.A.M. 1 , Pettengill, C. 1 , Bonfim, C.M. 1 , Ruiz, J. 1 ,  Azambuja, A.P. 1 , Medeiros, L. 1 , Setubal, D.C. 1 , Bitencourt, M.A. 1 ,  Oliveira, M.M. 1 , Coutinho, E.N. 1 , Zanis- Introduction: Chronic myeloid leukemia (CML) accounts for 2-3% of the leukemias in childhood. The only potential curative treatment is allogeneic hematopoietic stem cell transplantation (HSCT), although promising results achieved with imatinib mesylate in adults substantiate its use as a therapeutic alternative for children. The aim of this study is to analyze the outcomes of HSCT in pediatric patients regarding overall survival (OS) and main causes of death.
LONG TERM RESULTS OF ALLOGENEIC STEM CELL TRANSPLANT FOR CML IN PEDIATRIC PATIENTS: A STUDY OF 50 CASES TRANSPLANTED OVER 20 YEARS IN A SINGLE INSTITUTION
Materials and methods: Retrospective analysis of children aged 1-17 years, diagnosed with CML who underwent HSCT in a single institution in Brazil between jan/1984 and aug/2005. Survival was estimated by Kaplan-Meier curves. Log Rank test was used for comparison of continuous variables.
Results: Fifty patients were assessed, 31 male and 19 female. Median age of 13,5 years (1-17). Forty one patients (82%) were in first chronic phase (CP1) and 9 in advanced phases. The interval between diagnosis and HSCT had a median time of 17,5 months (5-84). The source of stem cells was bone marrow in 44 patients (88%), umbilical cord blood in 5 (10%) and peripheral blood stem cell in 1 (2%). Thirty nine patients (78%) underwent related HSCT and 11 (22%) unrelated donor HSCT. Conditioning regimens: busulfan and cyclophosphamide in 35 patients (70%) and TBI containing regimens in 15 (30%). Complete engraftment occurred in 82% of the transplants. Acute (a) graft-versus-hostdisease (GVHD) grades II-IV occurred in 44% of the patients, with 20% grade IV. Extensive chronic (c) GVHD occurred in 15/40 patients (38%). Fifteen patients (32%) relapsed after HSCT. Mortality in the study population was 48% and the main causes of death were: relapse in 6 patients (25%), a-GVHD in 6 (25%) and c-GVHD in 4 (17%). Estimated OS in 20 years was 50%, with a median survival of 1926 days. When analyzed separately, patients in CP1 who received related HSCT and immuneprophilaxis with three drugs (steroids, cyclosporine and methotrexate) had an estimated OS in 20 years of 70%.
Conclusions: 1) Long term follow up of these children with CML who underwent allogeneic HSCT demonstrate an OS of 50%, reaching 70% in low risk patients. 2) Main causes of death were relapse, acute and chronic GVHD. 
RISK FACTOR ANALISIS FOR SURVIVAL IN 125 UNRELATED TRANS-PLANTS FOR MALIGNANT DISEASES PERFORMED OVER TEN YEARS IN

